Research-use context: This article is provided for laboratory research and educational purposes only. It is not medical, therapeutic, diagnostic, veterinary, dosing or human-use guidance.
Different molecular research tools
CJC-1295 was developed as an analogue of growth-hormone-releasing hormone (GHRH). Ipamorelin belongs to a different class of growth-hormone secretagogues associated with the ghrelin receptor pathway. Combining names on a research product does not make them one molecule; they remain separate analytes.
Why the distinction matters analytically
For a blend containing CJC-1295 No DAC and ipamorelin, a single headline purity value can obscure the central analytical question: are both intended components present, correctly identified and present in the expected quantities? Blend testing should therefore distinguish the components wherever the method permits.
CJC-1295 naming requires care
Published human research on CJC-1295 includes a long-acting form designed to prolong exposure. “No DAC” material is not analytically identical to the drug-affinity-complex form used in that work. Researchers should avoid treating findings from one molecular form as direct evidence for another without qualification.
Reference
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295… J Clin Endocrinol Metab. 2006. PMID: 16352683.